Fundraising FoxFlorey Biosciences
Cambridge, US · Founded 2024 · Delaware corporation · 1 known investors
Find your way into Florey Biosciences
Sign up to see every warm intro you have to Florey Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Florey Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Florey Biosciences uses synthetic biology to engineer precision probiotics for human health, with a lead product, FLR-101, an engineered food-grade yeast probiotic developed as a medical food to manage antibiotic-related disruptions of the gut microbiome. It targets patients taking antibiotics and operates in the synthetic biology and microbiome therapeutics space.
Founders & leadership
Florey Biosciences was founded in 2024 by Andres Fernando Cubillos Ruiz.
AF
Andres Fernando Cubillos RuizFounder
RG
Raphael GayetNamed on SEC filing
Board
PH
Peter HuttBoard director
MS
Investors · 1
Also in the syndicate · 1
Seerave Ventureslead
Funding
SEC filings, press & company announcements$1.4M disclosed across 1 of 2 rounds · 2024–2025
- Undisclosed amountpre-seedOct 2024
Seerave Ventures (lead)
Source ↗
▶$1.4MraisedApr 2025 · 1 investors · BiotechnologyRule 506(b)
▶$1.4MraisedApr 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter HuttDirector
- Raphael GayetExecutive Officer
- Mark SmithDirector
- Andres Fernando Cubillos RuizExecutive Officer, Director
- Offering amount
- $4.4M
- Amount sold
- $1.4M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Primrose BioPrimrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms. The company serves pharmaceutical developers and contract manufacturers in the biopharmaceutical industry.
Life BiosciencesLife Biosciences is a biopharmaceutical company developing therapies focused on aging and age-related diseases, working across gene therapy and neuroscience programs. It advances drug candidates from discovery through clinical development.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Precision BioSciencesPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
AmbrosiabiosciencesAmbrosia Biosciences is a drug discovery company developing orally delivered, small molecule therapies for obesity and other metabolic disorders. It operates U.S.-based biology and chemistry laboratories along with an NMR facility and structural biology and computational chemistry capabilities to advance programs from hit to IND.
Companies working in the same space as Florey Biosciences.
In the news
Frequently asked questions
- What does Florey Biosciences do?
- Florey Biosciences uses synthetic biology to engineer precision probiotics for human health, with a lead product, FLR-101, an engineered food-grade yeast probiotic developed as a medical food to manage antibiotic-related disruptions of the gut microbiome. It targets patients taking antibiotics and operates in the synthetic biology and microbiome therapeutics space.
- Who founded Florey Biosciences?
- Florey Biosciences was founded by Andres Fernando Cubillos Ruiz in 2024.
- How much funding has Florey Biosciences raised?
- Florey Biosciences has disclosed $1.4M raised across 1 of its 2 known rounds.
- Where is Florey Biosciences headquartered?
- Florey Biosciences is headquartered in Cambridge, US.